Showing 1301-1310 of 3098 results for "".
- Rethinking the Safety of Stimulants in ADHDhttps://practicalneurology.com/columns/practice-management/rethinking-the-safety-of-stimulants-in-adhd/31322/Cardiovascular Safety of Stimulants in ADHD Treatment: An Update for CliniciansThe use of stimulants in treating Attention-Deficit/Hyperactivity Disorder (ADHD) has long been a cornerstone in managing this pervasive condition, which affects 5-7% of school-aged children and 3-5% of adults. However, r
- Window of Opportunity: Can We Expand Access to Acute Stroke Care?https://practicalneurology.com/diseases-diagnoses/stroke/PN0106acutestrokecare-pdf/31349/Stroke remains a critical concern in neurology, being the third leading natural cause of death and the foremost cause of long-term disability. According to the American Heart Association, strokes occur every 45 seconds in the United States, imposing an estimated economic burden of $56.8 billion annu
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31371/Integrating Clinical Trials into Neurological Practice: Balancing Benefits and ChallengesThe involvement of neurologists in clinical trials is gaining momentum, driven by the recognition of substantial benefits from academic researchers, the National Institutes of Health, and pharmaceutical companie
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31087/Establishing a successful hospital-based stroke program critically depends on unwavering support from hospital administration, a key requirement for Joint Commission on Accreditation of Healthcare Organizations (JCAHO) primary stroke center certification. In his December 2007 article for Practical N
- Vascular Clinichttps://practicalneurology.com/columns/practice-management/vascular-clinic/31339/At the February 2006 International Stroke Conference in Kissimmee, FL, leading vascular care experts convened to discuss advancements in stroke management and prevention. The event, hosted at the city’s convention center, facilitated the exchange of groundbreaking research and practical strategies a
- Vascular Clinichttps://practicalneurology.com/diseases-diagnoses/sleep/PN0206VacularClin-pdf/31348/Anticoagulation Strategies in Stroke Management: Insights from Ariel Sharon’s HemorrhageThe cerebral hemorrhage of former Israeli Prime Minister Ariel Sharon has reignited the debate on the appropriate use of anticoagulation in stroke patients. Sharon, who had suffered an ischemic stroke presumed to
- Editor's Messagehttps://practicalneurology.com/columns/practice-management/editors-message/31487/Financial Strain of Neurological Illnesses: A Hidden Burden Leading to Medical BankruptcyA February 2005 study published in *Health Affairs* underscores the severe financial impact of medical expenses on Americans, revealing that approximately two million individuals face “medical bankruptcy” annual
An Unusual Case of Descending Paralysis Caused by West Nile Virus
https://practicalneurology.com/diseases-diagnoses/ms-immune-disorders/an-unusual-case-of-descending-paralysis-caused-by-west-nile-virus/30523/Clinicians should consider a diagnosis of West Nile Virus in patients with acute flaccid paralysis, particularly those who come from areas where WNV is endemic.Real-World Experience Using Biomarker Testing for the Evaluation of Acute Traumatic Brain Injury
https://practicalneurology.com/diseases-diagnoses/tbi/real-world-experience-using-biomarker-testing-for-the-evaluation-of-acute-traumatic-brain-injury-1/32192/Integrating blood biomarker testing for traumatic brain injury into practice can help address some limitations with existing evaluative methods, leading to more timely and cost-effective diagnosis and improved health-related quality of life for affected individuals.Neuromuscular Notes: New and Emerging Therapies in ALS
https://practicalneurology.com/diseases-diagnoses/neuromuscular/neuromuscular-notes-new-and-emerging-therapies-in-als/32007/New therapies—including antisense oligonucleotides, mesenchymal stem cells, and kinase inhibitors—are in development to target specific pathogenic mechanisms identified in ALS.